FLT3 and acute myeloid leukemia: The presence of an atypical FLT3 mutation prompted the use of gilteritinib (cycle one, day 15) at 40 mg every other day, a FLT3i that is approved by the US Food and Drug Administration (FDA) as a single therapeutic agent in relapsed or refractory AML [8].